BLOODOMICS LTD
Company number 14720234 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
BLOODOMICS LTD - Analysis Report
Company Number: 14720234
Analysis Date: 2025-07-29 17:16 UTC
Risk Rating: LOW
The company is newly incorporated (March 2023) with a micro-entity reporting status, showing positive net current assets and no overdue filings. The modest current assets relative to current liabilities provide a comfortable short-term liquidity position. No indications of distress or regulatory non-compliance are evident.Key Concerns:
- Limited operational history: The company has less than two years of financial data, which limits trend analysis and assessment of business sustainability.
- Concentration of control: One individual (Dr. Nicholas Stephen Gleadall) holds 75-100% ownership and voting rights, which may present governance and succession risks.
- Small scale and resources: Being a micro-entity with only three employees may constrain growth potential and operational resilience.
- Positive Indicators:
- Strong liquidity position with net current assets of £39,219 against current liabilities of £9,830.
- Compliance with filing requirements: No overdue accounts or confirmation statements, indicating good regulatory discipline.
- Presence of directors with relevant professional backgrounds (computer programming and medicine) aligned with the IT consultancy SIC code.
- Due Diligence Notes:
- Verify the nature and sustainability of revenue streams and business model given the early stage and limited financial history.
- Review any contractual obligations or contingent liabilities not reflected in the balance sheet.
- Assess the corporate governance framework given the ownership concentration and whether any minority interests or external investors exist.
Sign in to generate a free AI analysis of this company — no password needed, just an email link.